gdc
FDA Approvals, News & UpdatesLung CancerNewsworthy

Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations

November 2018 Volume 4 – Lung Cancer

In January 2018, the FDA approved Gilotrif (afatinib; from Boehringer Ingelheim) for use as the first treatment in patients with metastatic non–small-cell lung cancer (NSCLC) associated with non-resistant EGFR mutations, as identified by an FDA-approved test.

Gilotrif is a second-generation tyrosine kinase inhibitor that was previously approved for patients with metastatic NSCLC and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, and for metastatic, squamous NSCLC that progressed with platinum-based chemotherapy.

This new indication for Gilotrif was based on durable responses in patients with metastatic NSCLC and nonresistant EGFR mutations other than exon 19 deletions or exon 21 L858R substitutions.

Overall, 66% of patients responded to treatment with Gilotrif. Among the 21 patients who responded to treatment, the response lasted 12 months or longer in half of the patients and 18 months or longer in one-third of patients.

The most common side effects with Gilotrif are diarrhea, rash, paronychia, dry skin, decreased appetite, nausea, vomiting, and pruritus.

Recommended For You
Breast CancerFDA Approvals, News & UpdatesImmunotherapy
First Immunotherapy Approved for Patients with Advanced or Metastatic Triple-Negative Breast Cancer Expressing PD-L1
In March 2019, the FDA approved Tecentriq (atezolizumab), a PD-L1 inhibitor, in combination with Abraxane (paclitaxel protein-bound), for use in adults with locally advanced or metastatic triple-negative breast cancer whose tumors cannot be removed by surgery and express PD-L1, as identified by an FDA-approved test. This is the first FDA-approved immunotherapy for patients with advanced or metastatic triple-negative breast cancer.
FDA Approvals, News & UpdatesGastric Cancer
Lonsurf Approved for Metastatic Gastric or Gastroesophageal Junction Cancer
In February 2019, the FDA approved Lonsurf for the treatment of patients with metastatic gastric (stomach) cancer or gastroesophageal junction adenocarcinoma. This drug was previously approved only for patients with metastatic colorectal cancer.
Last modified: December 11, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country